Showing results (261-270 of 389) with videos related to

Sort By:
Pageof 39
Clinical Lung Cancer|June 18, 2017
A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L StudyHidetoshi Hayashi, Yasutaka Chiba, Kazuko Sakai, et al.
Lung Cancer (Amsterdam, Netherlands)|June 27, 2020
Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry DatabaseKeigo Kobayashi, Kenzo Soejima, Koichi Fukunaga, et al.
Investigational New Drugs|May 25, 2012
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancerYoshikazu Hasegawa, Isamu Okamoto, Ken Takezawa, et al.
Breast Cancer (Tokyo, Japan)|November 30, 2011
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610BHidetoshi Hayashi, Junji Tsurutani, Taro Satoh, et al.
Cancer Science|October 6, 2018
Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencingEiji Iwama, Kazuko Sakai, Koichi Azuma, et al.
Clinical Lung Cancer|July 9, 2017
Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary FibrosisKohei Otsubo, Junji Kishimoto, Hirotsugu Kenmotsu, et al.
Molecular Oncology|November 1, 2020
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L)Kazuko Sakai, Takayuki Takahama, Mototsugu Shimokawa, et al.
The Oncologist|April 27, 2019
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNAKohei Otsubo, Kazuko Sakai, Masafumi Takeshita, et al.
International Journal of Cancer|March 15, 2021
Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weightingKazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori, et al.
Physics and Imaging in Radiation Oncology|December 1, 2025
A multi-institutional dummy run on segmentation variability and plan quality of stereotactic body radiotherapy for oligometastatic diseaseHideaki Hirashima, Yukinori Matsuo, Satoshi Ishikura, et al.
Pageof 39